Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
基本信息
- 批准号:8072925
- 负责人:
- 金额:$ 2.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-24 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAntigen ReceptorsAntigensBindingBiochemicalBiologicalBiological ProcessCatalysisCatalytic DomainCellular AssayChromosome abnormalityDNADNA DamageDNA Double Strand BreakDNA RepairDNA StructureDNA-dependent protein kinaseDefectDevelopmentDiseaseDisease OutcomeDouble Strand Break RepairEnzymesExhibitsExonucleaseFundingGene TargetingGenesGeneticGoalsHumanHypersensitivityImmune responseImmune systemImmunologic Deficiency SyndromesIndividualJ segment geneLactamaseLeadLymphocyteLymphoidLymphomaMalignant lymphoid neoplasmMolecularMusMutateMutationNonhomologous DNA End JoiningPatientsPhenotypePhosphorylationPredispositionPrincipal InvestigatorProcessProtein FamilyProtein-Serine-Threonine KinasesProteinsRAG1 geneRadiation ToleranceRegulationResearch PersonnelRoleSequence HomologySevere Combined ImmunodeficiencySite-Directed MutagenesisStagingSurfaceT-LymphocyteTranslationsV(D)J Recombinationartemisbaseendonucleasehuman diseasein vivoinsightmembermutantnucleaseprematureprogramsreceptorspleen exonucleasetumorigenesis
项目摘要
DESCRIPTION (provided by applicant): During the initial stages of the immune response against foreign antigens, a vast array of receptors expressed on the surface of B and T cells recognize and bind the myriad of foreign molecules. Diversity amongst the genes encoding the recognition regions of antigen receptors is generated through V(D)J recombination, a process in which individual V, D, and J gene segments are rearranged. Two types of activities are required for V(D)J recombination; lymphoid-specific factors, such as recombination activating genes 1 and 2 (RAG1/2), and the ubiquitously expressed non-homologous end-joining (NHEJ) DNA repair factors, such as Artemis. Mutations in Artemis are known to cause a human severe combined immunodeficiency syndrome associated with cellular radiosensitivity (RS-SCID). Recent evidence suggests that hypomorphic mutations in Artemis may also predispose to lymphoma in human patients. Artemis, a 76 kDa protein, possesses single strand 5' to 3' exonuclease activity and acquires endonucleolytic activity upon interaction with and phosphorylation by the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition to its role in V(D)J recombination, Artemis is also required for general DNA double strand break repair (DSB) and suppressing chromosomal aberrations, including translocations and telomeric fusions. It is not yet known whether both exo- and endonucleolytic activities or regulation by DNA-PKcs are required for each of the multiple functions of Artemis, nor is it clear what impact the Artemis mutations found in human patients have on its intrinsic biochemical activities. Thus, the goals of the specific aims described in this proposal are to use combined biochemical, cellular and genetic approaches to further elucidate the catalytic repertoire and in vivo roles of Artemis. These studies will provide a more clear understanding of the functions of Artemis in DNA repair processes and insights into the molecular mechanisms underlying immune system defects and predisposition to lymphoid malignancies in human patients.
描述(由申请人提供):在针对外来抗原的免疫反应的初始阶段,B细胞和T细胞表面表达的大量受体识别并结合无数的外来分子。编码抗原受体识别区的基因之间的多样性是通过V(D)J重组产生的,在这个过程中,单个的V、D和J基因片段被重新排列。V(D)J重组需要两种活性;淋巴特异性因子,如重组激活基因1和2 (RAG1/2),以及普遍表达的非同源末端连接(NHEJ) DNA修复因子,如Artemis。已知Artemis突变可引起与细胞放射敏感性相关的人类严重联合免疫缺陷综合征(RS-SCID)。最近的证据表明,阿尔忒弥斯的亚型突变也可能使人类患者易患淋巴瘤。Artemis是一种76 kDa的蛋白,具有单链5‘至3’外切酶活性,并通过与dna依赖性蛋白激酶催化亚基(DNA-PKcs)相互作用和磷酸化而获得核内溶活性。除了在V(D)J重组中发挥作用外,Artemis还需要用于一般的DNA双链断裂修复(DSB)和抑制染色体畸变,包括易位和端粒融合。目前尚不清楚Artemis的多种功能是否需要外核和内核溶解活性或DNA-PKcs的调节,也不清楚在人类患者中发现的Artemis突变对其内在生化活性有何影响。因此,本提案中描述的具体目标是利用生物化学,细胞和遗传方法的结合来进一步阐明Artemis的催化功能和体内作用。这些研究将使我们更清楚地了解Artemis在DNA修复过程中的功能,并深入了解人类患者免疫系统缺陷和淋巴细胞恶性肿瘤易感性的分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JoAnn Sekiguchi其他文献
JoAnn Sekiguchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JoAnn Sekiguchi', 18)}}的其他基金
Myeloablative conditioning and late complications in ARTEMIS-deficient SCID
ARTEMIS 缺陷 SCID 的清髓调理和晚期并发症
- 批准号:
9251366 - 财政年份:2017
- 资助金额:
$ 2.29万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8582506 - 财政年份:2010
- 资助金额:
$ 2.29万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8204498 - 财政年份:2010
- 资助金额:
$ 2.29万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8040274 - 财政年份:2010
- 资助金额:
$ 2.29万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8386672 - 财政年份:2010
- 资助金额:
$ 2.29万 - 项目类别:
Mechanism and regulation of DNA end processing in V(D)J recombination and repair
V(D)J重组和修复中DNA末端加工的机制和调控
- 批准号:
8116793 - 财政年份:2010
- 资助金额:
$ 2.29万 - 项目类别:
Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
- 批准号:
6993660 - 财政年份:2005
- 资助金额:
$ 2.29万 - 项目类别:
Mechanism and regulation of DNA end processing in V(D)J recombination and repair
V(D)J重组和修复中DNA末端加工的机制和调控
- 批准号:
8097247 - 财政年份:2005
- 资助金额:
$ 2.29万 - 项目类别:
Mechanism and regulation of DNA end processing in V(D)J recombination and repair
V(D)J重组和修复中DNA末端加工的机制和调控
- 批准号:
8488394 - 财政年份:2005
- 资助金额:
$ 2.29万 - 项目类别:
Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
- 批准号:
7555918 - 财政年份:2005
- 资助金额:
$ 2.29万 - 项目类别:
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 2.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 2.29万 - 项目类别:
Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 2.29万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 2.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 2.29万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 2.29万 - 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 2.29万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 2.29万 - 项目类别:
Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 2.29万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
9922602 - 财政年份:2020
- 资助金额:
$ 2.29万 - 项目类别:














{{item.name}}会员




